CurrentAetnaPolicy 0723

Rotavirus Vaccine

This policy governs coverage and medical necessity determinations for FDA-approved rotavirus vaccines (RotaTeq and Rotarix) for prevention of rotavirus gastroenteritis in infants, and applies to Aetna plan adjudication (check specific member benefit plans for preventive service exclusions).

Policy Summary

PayerAetna

PolicyRotavirus Vaccine

Policy CodePolicy 0723

Change TypeNo material change

Effective DateApr 4, 2006

Next Review DateAug 8, 2024

Key ActionVerify that rotavirus vaccine administration meets FDA/ACIP age and schedule criteria (initiate at ≥6 weeks and complete series by 8 months) before billing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Vaccines referenced

8 monthsMax completion age

6 weeksMin initiation age

3Codes listed

Coverage and Medical Necessity Criteria

Medical Necessity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Primary coverage criteria: 1) Vaccine is an FDA-approved rotavirus vaccine (RotaTeq [RV5] or Rotarix [RV1]). 2) Vaccine is administered for the prevention of rotavirus gastroenteritis in infants. 3) Initiation and completion of the vaccine series occur within FDA/ACIP-recommended age windows: first dose at or after 6 weeks of age and before 15 weeks of age (ACIP maximum for dose 1); minimum interval of 4 weeks between doses; and all doses completed by 8 months and 0 days of age (ACIP). 4) Product-specific schedule constraints are met: for RotaTeq (RV5) a 3-dose series with first dose between 6 and 12 weeks and all doses completed by 32 weeks of age per FDA labeling (subsequent doses at 4–10 week intervals); for Rotarix (RV1) a 2-dose series with first dose beginning at 6 weeks and second dose at least 4 weeks later and prior to 24 weeks per manufacturer, with ACIP requiring completion by 8 months of age.age and dosing windows per product and ACIP

Policy bases coverage on FDA-approved vaccines and ACIP recommendations.

Experimental and Investigational

Experimental/Investigational stance: Use of rotavirus vaccines for any indication other than prevention of rotavirus gastroenteritis in infants less than 8 months of age is considered experimental and investigational because effectiveness for other indications has not been established.

Policy explicitly restricts coverage to the listed indication.

Some Aetna member benefit plans include exclusions for preventive services. Because rotavirus vaccination is provided as a preventive service for infants, coverage may be limited or excluded depending on the member’s specific plan. Verify the member’s benefit plan description and coverage details before administering or billing for rotavirus vaccine.

This Clinical Policy Bulletin is provided to assist in administering plan benefits but does not constitute an offer of coverage or medical advice. It contains a partial, general description of plan or program benefits and is not a contract; treating providers remain responsible for medical advice and treatment, and the bulletin may be updated or changed.

Use of rotavirus vaccine for indications other than the prevention of rotavirus gastroenteritis in infants younger than 8 months of age is considered experimental, investigational, and not medically necessary under this policy because effectiveness for other indications has not been established. Do not bill for administration outside the covered infant indication without confirming medical necessity and plan coverage.

Billing and Coding

Covered CPT/HCPCS Codes (if selection criteria are met)CPTCovered

90680	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use.
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use.

Covered ICD-10 Codes (if selection criteria are met)ICD-10Covered

Z23	Encounter for immunization [rotavirus gastroenteritis]

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior authorization: No explicit prior authorization requirement is stated in this policy. Coverage is determined by meeting FDA/ACIP-recommended age and clinical criteria for rotavirus vaccination (i.e., infants <8 months for FDA‑approved vaccines). Providers should verify member-specific benefit plan requirements prior to administration in case a plan requires prior authorization.

Check member benefit plan for any plan-specific prior authorization or preventive service exclusion
Confirm patient age and that administration follows ACIP/CDC schedule recommendations

Denial Risk

Preventive Service Exclusion Risk

Preventive service exclusion risk: Some Aetna plans exclude coverage of preventive services. Providers must check the member’s benefit plan description to determine whether rotavirus vaccine administration is covered or excluded under that specific plan.

Verify coverage through eligibility and benefits prior to billing
If preventive services are excluded, obtain member financial responsibility acknowledgement as required by the plan

Note

Not Specified / Additional Provider Actions

Not specified in these chunks: The policy excerpts do not list step therapy, sequencing requirements, or explicit authorization/denial triggers. Preserve clinical indications per medical necessity and experimental/investigational statements in the full policy.

Follow ACIP/CDC recommendations and the policy's medical necessity criteria for eligible infants
Consult full policy appendix for administration schedule

Billing Rule

Coding and Documentation

Coding and documentation: Use the appropriate CPT/HCPCS and ICD-10 codes when billing for rotavirus vaccination and associated immunization encounters. Ensure documentation supports medical necessity and member eligibility.

Covered CPT codes when criteria met: 90680 (Rotavirus vaccine, pentavalent, RV5, 3-dose schedule, oral)
Covered CPT codes when criteria met: 90681 (Rotavirus vaccine, human attenuated, RV1, 2-dose schedule, oral)
ICD-10: Z23 (Encounter for immunization) — document as immunization encounter
Retain vaccine administration record, date of birth, lot numbers, and consent in the medical record

Documentation Required

Clinical Policy Bulletins

Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute medical advice. Treating providers are solely responsible for medical advice and treatment of members. Providers should consult the full Clinical Policy Bulletin for complete policy details, review history, and definitions.

Refer to Clinical Policy Bulletin Notes and policy history for updates and definitions
Understand that CPBs are not offers of coverage and do not replace clinical judgment

Background and Rationale

Rotavirus is a leading cause of severe diarrhea in infants and young children and is associated with substantial emergency department visits and hospitalizations. FDA-approved oral vaccines (RotaTeq and Rotarix) are indicated for the prevention of rotavirus gastroenteritis in infants and, together with ACIP guidance, form the basis for this policy’s coverage criteria. Clinical trials and public health data support vaccination to reduce severe rotavirus disease and related hospitalizations, while safety monitoring has included evaluation for intussusception.

Vaccine Products and Dosage Definitions

RotaTeq (RV5) — dosing and timing

Vaccine and formulationRotaTeq (RV5) — pentavalent live oral rotavirus vaccine (targets G1–G4).

Series and doses3-dose series administered orally at ages commonly given at 2, 4, and 6 months (per ACIP).

Initiation windowFirst dose should be administered between 6 and 12 weeks of age; immunization should not be initiated for infants older than 12 weeks (FDA labeling).

Dose intervalsSubsequent doses should be administered at 4 to 10-week intervals (FDA labeling).

Completion age / latest doseAll 3 doses should be administered by 32 weeks of age per FDA labeling; ACIP/ policy requires all doses by 8 months (8 months, 0 days).

Contraindications / safety noteSafety and efficacy not established for infants <6 weeks or >32 weeks of age; contraindicated with serious allergic reaction to vaccine components or a prior dose.

Rotarix (RV1) — dosing and timing

Vaccine and formulationRotarix (RV1) — human attenuated live oral rotavirus vaccine (targets G1, G3, G4, G9).

Series and doses2-dose series administered orally (commonly at 2 and 4 months per ACIP).

Initiation windowFirst dose should be given between 6 and 14 weeks of age (manufacturer).

Dose intervalInterval between doses should be at least 4 weeks (manufacturer).

Completion age / latest doseManufacturer: series should be completed by 24 weeks of age; ACIP/policy: all doses should be administered by 8 months (8 months, 0 days).

Safety / contraindicationsRotarix safety studies did not show increased intussusception risk; contraindicated in individuals with history of certain chronic gastrointestinal disease or severe allergic reaction to vaccine components.